A review.Drug Metabolism and Pharmacokinetics (DMPK) researchers have been gaining the capability to preclinically predict human PK, and have contributed to pharmaceutical companies by drastically reducing the dropout rate caused by a lack of systemic exposure of candidate drugs in first-in human studies (Phase-1).The article discusses the importance of model-based drug development (MBDD) to DMPK researchers.